BUZZELLI, GIAMPIERO
 Distribuzione geografica
Continente #
NA - Nord America 1.094
EU - Europa 973
AS - Asia 257
AF - Africa 10
OC - Oceania 3
SA - Sud America 1
Totale 2.338
Nazione #
US - Stati Uniti d'America 1.089
RU - Federazione Russa 411
IE - Irlanda 136
SE - Svezia 125
HK - Hong Kong 91
UA - Ucraina 81
IT - Italia 74
SG - Singapore 67
DE - Germania 50
CN - Cina 45
FI - Finlandia 36
CH - Svizzera 33
IN - India 26
TR - Turchia 16
GB - Regno Unito 15
JO - Giordania 9
CI - Costa d'Avorio 8
CA - Canada 5
FR - Francia 5
NL - Olanda 4
NZ - Nuova Zelanda 3
BE - Belgio 2
EC - Ecuador 1
IR - Iran 1
JP - Giappone 1
KE - Kenya 1
KR - Corea 1
RS - Serbia 1
SC - Seychelles 1
Totale 2.338
Città #
Chandler 162
Jacksonville 140
Dublin 136
Fairfield 101
Ashburn 64
Hong Kong 60
Cambridge 58
Singapore 55
Wilmington 51
Woodbridge 44
Buffalo 36
Princeton 36
Bern 33
Houston 32
Seattle 32
Boardman 30
Medford 22
Ann Arbor 21
Boston 21
Mumbai 21
Lawrence 17
Altamura 16
Shanghai 15
Beijing 14
Izmir 11
Abidjan 8
Norwalk 8
Santa Clara 7
Los Angeles 6
New York 6
Auburn Hills 5
Florence 5
Milan 5
Philadelphia 5
Dearborn 4
Falls Church 4
Frankfurt Am Main 4
Salerno 4
San Diego 4
Toronto 4
Washington 4
Andover 3
Bremen 3
Hillsboro 3
Kumeu 3
Verona 3
Ahmedabad 2
Brussels 2
Guangzhou 2
Kent 2
Kunming 2
Meppel 2
New Delhi 2
Redmond 2
Ardabil 1
Arezzo 1
Atlanta 1
Belgrade 1
Central 1
Civitanova Marche 1
Clifton 1
Costabissara 1
Dallas 1
Guayaquil 1
Hefei 1
Montréal 1
Nanjing 1
Ningbo 1
Old Bridge 1
Pune 1
Saint Petersburg 1
San Mateo 1
San Severino Marche 1
Sedico 1
Seoul 1
Taizhou 1
Yoshinochō 1
Totale 1.365
Nome #
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 113
"Inapparent" hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease 112
Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. 111
Interferon and thymosin combination therapy in naive patients with chronic hepatitis C. Preliminary results 99
Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection 98
Systemic hemodynamics and renal function in cirrhotic patients during plasma volume expansion. 97
Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis 87
Alterazioni del sistema pPAF-AH/PAF in pazienti con infezione cronica da HCV 83
Chemotherapy of primary and secondary liver cancer: is it useful? 80
Therapeutic and antilipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease: Preliminary results 79
Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis 78
Alcoholic hepatopathy in Tuscany. Preliminary results of a multicenter study 75
Epidemiological aspects of chronic viral hepatitis 69
Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm. 69
Can serum bile acid determination substitute BSP loading test in detecting and monitoring chronic liver diseases? 66
[Viral liver cirrhosis: natural course, pathogenesis and clinical implications of the complications] 65
Action of acute ethanol intake on rat biliary secretion: effect of epomediol. 64
Functional and ultrastructural changes in the liver during CDCA treatment. 61
EFFECTS OF RECOMBINANT HUMAN GAMMA-INTERFERON ON ADVANCED HEPATOCELLULAR CARCINOMA 59
Effects of recombinant human gamma-interferon on advanced hepatocellular carcinoma 58
Long course and prognostic factors of virus-induced cirrhosis of the liver. 55
Epatite da virus C e terapia interferonica 55
The bromosulphthalein loading test in chronic alcoholic liver diseases. 54
Interferon alfa + Ribavirin (RIBA) therapy for chronic hepatitis C (CHC) patients non responders to interferon alfa monotherapy 53
Therapy of chronic active hepatitis C with alfa interferon: effectiveness and prognostic factors 52
Plasma PAF-AH biological activity decreases in patients with HCV chronic infection 50
Epidemiological aspects of chronic viral hepatitis 49
L'Impiego dell'INterferone Alfa Ricombinante nel Trattamento della Cirrosi Attiva anti-HCV positiva. 48
THERAPY OF CHRONIC ACTIVE HEPATITIS C WITH ALFA INTERFERON:EFFECTINEVESS AND PROGNOSTIC FACTORS 44
La Cirrosi Epatica Virus-correlata: Storia Naturale, patogenesi e implicazioni cliniche dellew complicanze. 44
Terapia interferonica dell'epatite cronica attiva HCV-correlata con e senza cirrosi 41
Elementi epidemiologici e di importanza sociale delle epatiti virali. 38
Recenti dati sulle epatiti virali acute e croniche 36
Virological analysis of the healthy HCV carrier state: prognostic factors and HCV persistence in non viraemic subjects 36
Modifications of Plasma PAF-AH activity in Patients with Chronic HCV infection 34
Therapy Of Chronic Active Hepatitis-C With Alpha-Interferon - Effectiveness And Prognostic Factors 29
Totale 2.341
Categoria #
all - tutte 7.392
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.392


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020233 0 0 0 32 20 42 26 41 19 17 33 3
2020/2021229 27 5 27 19 0 36 9 26 13 31 12 24
2021/2022199 2 28 4 7 3 3 3 10 2 3 67 67
2022/2023602 52 60 36 34 66 118 77 34 69 4 13 39
2023/2024218 14 19 36 15 9 27 6 75 4 1 6 6
2024/2025538 38 176 117 207 0 0 0 0 0 0 0 0
Totale 2.341